Press Releases Acrivon Therapeutics, Inc.

Equities

ACRV

US0048901096

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
7.25 ^USD	-6.09%		0.00%	+47.36%

May. 14	Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	North American Morning Briefing : More Earnings -2-	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference	May. 29	GL
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights	May. 14	GL
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event	Apr. 24	GL
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316	Apr. 16	GL
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368	Apr. 10	GL
Acrivon Therapeutics Announces $130 Million Private Placement Financing	Apr. 09	GL
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	Mar. 28	GL
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316	Mar. 05	GL
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors	Mar. 04	GL
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors	Mar. 04	AQ
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference	Feb. 27	GL
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors	Feb. 08	GL
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	GL
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jan. 12	GL
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 04	GL
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 04	AQ
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer	Jan. 03	GL
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer	Nov. 28	GL
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer	Nov. 28	AQ
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Nov. 21	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Acrivon Therapeutics, Inc.

Equities

ACRV

US0048901096

Press Releases

Filters